Enanta Pharma (ENTA) Misses Q4 EPS by 2c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.27), $0.02 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $20.32 million versus the consensus estimate of $22.87 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
• 'We expect salesforce.com (CRM) to capture a meaningful share of next-gen agentic workflows': Cantor